ANQ 9040

Drug Profile

ANQ 9040

Latest Information Update: 25 Mar 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Baxter International
  • Class Androstanes; Azasteroids; Muscle relaxants
  • Mechanism of Action Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Muscle hypertonia

Most Recent Events

  • 25 Mar 1999 No-Development-Reported for Hypertonia in USA (Unknown route)
  • 07 Nov 1995 Phase-I clinical trials for Hypertonia in USA (Unknown route)
  • 07 Nov 1995 Two studies have been added to the pharmacodynamics and adverse events sections ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top